Clinical Trials Logo
  1. Home
  2. Pneumococcal Infection
  3. NCT05696080

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) — STRIDE-8  

Pneumococcal Infection Clinical Trial

Official title:
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 18 to 64 Years of Age With Increased Risk for Pneumococcal Disease

Clinical Trial Summary

The primary objectives of this study are to evaluate the safety and tolerability of the pneumococcal 21 valent conjugate vaccine (V116), and to evaluate the serotype-specific opsonophagocytic activity (OPA) post-vaccination with V116 and PCV15 (a pneumococcal conjugate vaccine that includes 15 serotypes) + PPSV23 (comprised of the polysaccharides from 23 of the serotypes causing disease in adults) post-vaccination. within each vaccination group separately.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05696080
Study type Interventional
Source Merck Sharp & Dohme LLC
Contact
Status Completed
Phase Phase 3
Start date February 13, 2023
Completion date February 16, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT02463539 - Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis N/A
Completed NCT03095326 - Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia Phase 4
Completed NCT02260882 - Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902) Phase 4
Completed NCT02572635 - A Phase I Study to Evaluate the Safety and Immunogenicity of PnuBioVax Phase 1
Completed NCT01654263 - A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine Phase 2
Completed NCT01531322 - A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects Phase 1
Completed NCT00496093 - Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011) Phase 3
Completed NCT02062281 - Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults Phase 4
Completed NCT00133549 - 9-valent CRM 197 Pneumococcal Phase 2
Completed NCT03467984 - A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants Phase 2
Active, not recruiting NCT03489018 - The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants Phase 4
Recruiting NCT02463578 - Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis N/A
Completed NCT00535730 - ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED) Phase 3
Completed NCT02558751 - Pneumonia Vaccine in Aging HIV Positive Individuals Phase 0
Completed NCT02515240 - Immune Response to Pneumococcal Vaccination in HIV Infected Individuals Phase 0
Completed NCT00560950 - Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007) Phase 3
Completed NCT05425732 - Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3) Phase 3
Completed NCT03619252 - Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Phase 4
Not yet recruiting NCT03549208 - A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Phase 1
Not yet recruiting NCT03341195 - Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan N/A